Orifarm Group AS - Strategic SWOT Analysis Review

Orifarm Group AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Report Scope

• Business description - A detailed description of the company’s operations and business divisions.
• Corporate strategy - The analyst’s summarization of the company’s business strategy.
• SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives’ employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Orifarm Group A/S (Orifarm), a subsidiary of Habico A/S. It is a healthcare company. It focuses on the manufacturing, commercialization, and trading of pharmaceutical products. The company imports, repackages, and sells medicine; provides off-patent, small-molecule medicine; and supplies consumer healthcare products. Orifarm's product portfolio includes pharmaceuticals for primary and secondary care, over-the-counter (OTC) products, and consumer healthcare products. The company supplies its products to wholesalers, pharmacies, hospitals, and patients. It has an operational presence in Europe and the US. Orifarm is headquartered in Odense, Denmark

Orifarm Group AS Key Recent Developments

• May 01, 2026: Orifarm Welcomes International Pharma Executive to the Board of Directors
• Mar 05, 2026: Orifarm Delivers Record Results and Sets New Growth Trajectory
• Jan 05, 2026: New Senior Executive to Realize Orifarm’s Growth Ambitions Within Generics
• Nov 03, 2025: Orifarm Strengthens Board of Directors With New International Pharma Profile

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.